Abstract: A biomarker composition for predicting susceptibility to a therapeutic agent for neurofibromatosis by using Ras activity; and a pharmaceutical composition for preventing or treating neurofibromatosis, including a Ras activity inhibitor. The biomarker composition can accurately diagnose susceptibility to a therapeutic agent for neurofibromatosis by measuring the expression levels of a GTP-bound and activated Ras (Ras-GTP) protein and an activated p-ERK protein or a gene encoding the same in a biological sample of an individual. The pharmaceutical composition inhibits the activity of Ras proteins, and thus can be effectively used for the prevention or treatment of neurofibromatosis in which the activity of the Ras proteins is increased.

Abstract: The present invention relates to a composition for the differential diagnosis of malignant peripheral nerve sheath tumor (MPNST), a differential diagnosis kit comprising same, a method for providing information required for differential diagnosis of MPNST using same, a method for screening materials for preventing, alleviating, and treating MPNST, and the like. Using the composition capable of detecting the protein marker of the present invention has the effect of making it possible to predict and diagnose whether a malignant tumor has occurred in a patient with neurofibromatosis type 1.

Abstract: This application relates to a system for verifying data access and a method thereof. In one aspect, the system includes a service module for receiving a data access request for an original data from a client, and sending a first verification data to the client. The system also includes a verification module for receiving a first data eigenvalue corresponding to the original data from the service module, and generating a first verification fingerprint corresponding to the first data eigenvalue. The system further includes a data module for generating the first verification data by receiving the first verification fingerprint to embed into the original data, and generating a first integrity value by hashing the first verification data. The system further includes a verification database for storing data access information comprising the first data eigenvalue, the first verification fingerprint and the first integrity value in one record identified as the original data.